Drugs / 4SCAR T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05459870 | Jun 2026 → Dec 2029 expected | autoimmune disease | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06435897 | May 2024 → Jul 2027 expected | autoimmune disease | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR-T cells | “clinical evidence to support the use of 4SCAR-T cells and MSCs in the treatment of autoimmune diseases.” NCT06435897 ↗ |
| Action | Deplete | “The activated CAR-T cells can target and kill B cells.” NCT05459870 ↗ |
| Modality | Cell therapy | “CAR-T cell technology” NCT05459870 ↗ |
| Route | Intravenous | “via IV” NCT05459870 ↗ |
| Target | CD19 | “Besides targeting CD19, specific CARs targeting other B cell surface molecules including BCMA, CD138, and BAFF-R will also be included in the treatment regimen.” NCT05459870 ↗ |